XML 33 R21.htm IDEA: XBRL DOCUMENT
v3.19.1

Subsequent Events | 3 Months Ended
--- | ---
Mar. 31, 2019
Subsequent Events [Abstract] |
Subsequent Events | 15. Subsequent Events Royalty Purchase Agreement with Aronora, Inc. On April 7, 2019, the Company entered into a Royalty Purchase Agreement (the “Aronora Royalty Purchase Agreement”) with Aronora, Inc., a private research and development company headquartered in Portland, Oregon (“Aronora”). Pursuant to the terms of the Aronora Royalty Purchase Agreement, the Company, subject to certain customary closing conditions, will purchase from Aronora the rights to potential royalty payments and a portion of the potential milestone payments associated with five hematology drug products in development: three anti-thrombotic candidates subject to Aronora’s collaboration with Bayer Pharma AG (“Bayer”), one of which is subject to an option by Bayer (the “Bayer Licensed Products”) and two additional early stage hematology candidates, including one in early stage clinical trials (the “non-Bayer Licensed Products,” together with the Bayer Licensed Products, the “Products”). Under the terms of the Aronora Royalty Purchase Agreement, the Company will make an initial $6.0 million payment to Aronora at the closing of the transaction (the “Closing Amount”) subject to the fulfillment of certain pre-closing conditions contained in the Aronora Royalty Purchase Agreement. The transaction is expected to close no later than the third quarter of 2019, and the Aronora Royalty Purchase Agreement will terminate if all pre-closing conditions are not fulfilled within ninety days and the parties do not extend the Aronora Royalty Purchase Agreement prior thereto. The Company is required to make an additional $1.0 million payment (up to a total of $3.0 million) for each of the three Bayer Licensed Products that are active as of September 1, 2019. The Company will receive, on average, low single-digit royalties on future sales of the Bayer Licensed Products (net of certain royalties payable to third parties) and 10% of all future developmental, regulatory and sales milestones related to the Bayer Licensed Products payable after the closing of the transaction excluding the payment of any milestone associated with Bayer exercising its option on one of the Bayer Licensed Products. In addition, the Company will purchase from Aronora the right to receive low single- digit royalties on potential sales of the non-Bayer Licensed Products and 10% of all future payments, including upfront payments, option payments and developmental, regulatory and sales milestone payments on potential future sales of the non-Bayer Licensed Products. The above future payment percentages will be reduced to 5% upon the Company’s receipt of two times the total cumulative amount of consideration paid by the Company to Aronora. Pursuant to the Aronora Royalty Purchase Agreement, if the Company receives over $250 million in cumulative royalties on net sales per Product, the Company will be required to pay associated tiered milestones payments to Aronora in an aggregate amount of up to $85 million per Product. The Aronora Royalty Purchase Agreement contains customary representations, warranties, covenants and indemnities. The Aronora Royalty Purchase Agreement will terminate six months following receipt by the Company of all royalty payments to which it is entitled thereunder. Aronora can terminate the Aronora Royalty Purchase Agreement if the Company fails to make payments thereunder in a timely fashion (after the expiration of any applicable cure period). Sonnet BioTherapeutics, Inc. On May 6, 2019, the Company executed an amendment to a license agreement with Sonnet BioTherapeutics, Inc. that entitles XOMA to potential future milestones and royalties on certain development stage assets.

X
- References No definition available. + Details
Name: | us-gaap_SubsequentEventsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 855 -URI http://asc.fasb.org/topic&trid=2122774 + Details
Name: | us-gaap_SubsequentEventsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration